ReviewCancer immunology, immunotherapy : CII2006
Adoptive T cell therapy of solid cancers.
Review in Cancer immunology, immunotherapy : CII, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment.Frontiers in immunology · 2024Review
- The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2019Review
- Embryonic Fibroblasts Promote Antitumor Cytotoxic Effects of CD8Frontiers in immunology · 2018Article
- Targeted immune therapy of ovarian cancer.Cancer metastasis reviews · 2015Review
- Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy.ImmunoTargets and therapy · 2014Review
- Potential of human γδ T cells for immunotherapy of osteosarcoma.Molecular biology reports · 2013Review
- Immunity and immune suppression in human ovarian cancer.Immunotherapy · 2011Article
- Generation of functional CD8+ T cells by human dendritic cells expressing glypican-3 epitopes.Journal of experimental & clinical cancer research : CR · 2010Article
- Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.Clinical & developmental immunology · 2010Review
- Magnetic resonance imaging-guided adoptive cellular immunotherapy of central nervous system tumors with a T1 contrast agent.Magnetic resonance in medicine · 2009Article
- Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Article
- Establishment of transplantable porcine tumor cell lines derived from MHC-inbred miniature swine.Blood · 2007Article
- Article
- Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28.Journal of immunotherapy (Hagerstown, Md. : 1997)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The development of immune-based approaches for the treatment of cancer has been actively investigated for many years. One strategy that has emerged as a potentially effective strategy for the treatment of aggressive established malignancies is adoptive T cell therapy. The power of this approach has been repeatedly observed in preclinical animal models. However, moving from homogeneous animal models to the heterogeneous human clinical setting has been very difficult. It is only in recent times that we have been able to pinpoint the problems of the clinical translation of adoptive T cell therapy. Some of the major problems are sources of tumor-specific T cells, ex vivo expansion, persistence, and anti-tumor activity. This review overviews the nature of these problems and some of the emerging solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.